PLX - יחס שווי שוק לרווח וקצב צמיחה Protalix BioTherapeutics, Inc

Protalix BioTherapeutics maintains a niche in orphan disease therapy through unique patent protection. The ProCellEx technology provides a competitive edge by synthesizing proteins in plant cells, which is more cost-effective and safer than traditional methods. The level of undervaluation based on the PEG ratio demonstrates value dynamics, where the value of 0.00 characterizes this level. Enzyme development relies on a strategic alliance with Chiesi and other partners.

Protalix BioTherapeutics ensures stable access to plant-based biologics through strictly controlled international express logistics. The fundamental PEG indicator compares the current P/E multiple with earnings growth rates to determine the business value relative to its actual return; a value below one signals that the model is undervalued, allowing an investor to identify the asset's potential by analyzing the trend on this chart.